NasdaqGS:CMPSBiotechs
COMPASS Pathways (CMPS) Is Up 7.1% After FDA Priority Status For COMP360 Psilocybin Therapy
In April 2026, COMPASS Pathways reported that the FDA granted its COMP360 psilocybin therapy for treatment-resistant depression both rolling NDA review and selection for the Commissioner's National Priority Voucher program, providing enhanced agency engagement and a potentially shorter review window while maintaining safety and efficacy standards.
The company also entered a collaboration with Osmind to study how independent psychiatry practices could deliver psychedelic treatments at scale,...